Eiger BioPharmaceuticals. has been granted a patent for a method to treat hepatitis delta virus (HDV) infection using a combination of lonafarnib and ritonavir. The treatment involves administering an amorphous co-precipitate of these compounds, which is free of crystalline forms, at specified daily doses. GlobalData’s report on Eiger BioPharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eiger BioPharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Eiger BioPharmaceuticals's grant share as of June 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Combination treatment for hepatitis delta virus (hdv) infection
The granted patent US12029819B2 outlines a method for treating hepatitis delta virus (HDV) infections in human patients through the oral administration of an amorphous co-precipitate. This co-precipitate consists of lonafarnib or its pharmaceutically acceptable salt, combined with ritonavir or its pharmaceutically acceptable salt. The formulation is characterized by being substantially free of crystalline forms and is administered at a daily dosage of lonafarnib ranging from 50 mg to 200 mg, either once or twice daily. The treatment duration can vary, with options for administration lasting from a minimum of 30 days to potentially the patient's lifetime, contingent upon the effectiveness in maintaining HDV at a low level.
Additionally, the patent specifies that the amorphous co-precipitate can be formulated into various dosage forms, including tablets, caplets, gelcaps, or capsules. The claims also allow for the inclusion of a gastrointestinal modifying agent to enhance treatment efficacy. The co-precipitate's composition can be adjusted, with the ratio of lonafarnib to ritonavir ranging from 0.5:1 to 2:1 by weight. This method is particularly aimed at patients suffering from chronic HDV infections, providing a structured approach to managing this viral condition through a novel pharmaceutical formulation.
To know more about GlobalData’s detailed insights on Eiger BioPharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
